To assess our hypothesis, we analyzed the responses and treatment outcomes of 235 patients with advanced NSCLC treated with platinum-based therapy and the association of treatment response and outcomes with BCL2 -938C>A) (rs2279115) and BAX -248G>A (rs4645878) SNP status. The gene discussed is BAX; the disease is non-small cell lung carcinoma.